全文获取类型
收费全文 | 30962篇 |
免费 | 2372篇 |
国内免费 | 71篇 |
专业分类
耳鼻咽喉 | 355篇 |
儿科学 | 1065篇 |
妇产科学 | 734篇 |
基础医学 | 4855篇 |
口腔科学 | 664篇 |
临床医学 | 3450篇 |
内科学 | 6096篇 |
皮肤病学 | 629篇 |
神经病学 | 2915篇 |
特种医学 | 891篇 |
外国民族医学 | 1篇 |
外科学 | 3795篇 |
综合类 | 206篇 |
一般理论 | 26篇 |
预防医学 | 2495篇 |
眼科学 | 612篇 |
药学 | 2204篇 |
中国医学 | 33篇 |
肿瘤学 | 2379篇 |
出版年
2023年 | 179篇 |
2022年 | 254篇 |
2021年 | 565篇 |
2020年 | 464篇 |
2019年 | 621篇 |
2018年 | 686篇 |
2017年 | 618篇 |
2016年 | 741篇 |
2015年 | 730篇 |
2014年 | 961篇 |
2013年 | 1362篇 |
2012年 | 1899篇 |
2011年 | 1807篇 |
2010年 | 1084篇 |
2009年 | 979篇 |
2008年 | 1557篇 |
2007年 | 1607篇 |
2006年 | 1539篇 |
2005年 | 1500篇 |
2004年 | 1508篇 |
2003年 | 1336篇 |
2002年 | 1272篇 |
2001年 | 628篇 |
2000年 | 636篇 |
1999年 | 628篇 |
1998年 | 386篇 |
1997年 | 302篇 |
1996年 | 299篇 |
1995年 | 284篇 |
1994年 | 229篇 |
1993年 | 238篇 |
1992年 | 432篇 |
1991年 | 461篇 |
1990年 | 463篇 |
1989年 | 447篇 |
1988年 | 371篇 |
1987年 | 359篇 |
1986年 | 322篇 |
1985年 | 385篇 |
1984年 | 260篇 |
1983年 | 238篇 |
1982年 | 198篇 |
1981年 | 153篇 |
1979年 | 222篇 |
1978年 | 172篇 |
1977年 | 158篇 |
1976年 | 140篇 |
1975年 | 148篇 |
1974年 | 169篇 |
1973年 | 146篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Fernanda Hansen Daniela Fraga de Souza Simone da Luz Silveira Ana Lúcia Hoefel Júlia Bijoldo Fontoura Ana Carolina Tramontina Larissa Daniele Bobermin Marina Concli Leite Marcos Luiz Santos Perry Carlos Alberto Gon?alves 《Metabolic brain disease》2012,27(4):531-539
Methylglyoxal is a dicarbonyl compound that is physiologically produced by enzymatic and non-enzymatic reactions. It can lead to cytotoxicity, which is mainly related to Advanced Glycation End Products (AGEs) formation. Methylglyoxal and AGEs are involved in the pathogenesis of Neurodegenerative Diseases (ND) and, in these situations, can cause the impairment of energetic metabolism. Astroglial cells play critical roles in brain metabolism and the appropriate functioning of astrocytes is essential for the survival and function of neurons. However, there are only a few studies evaluating the effect of methylglyoxal on astroglial cells. The aim of this study was to evaluate the effect of methylglyoxal exposure, over short (1 and 3?h) and long term (24?h) periods, on glucose, glycine and lactate metabolism in C6 glioma cells, as well as investigate the glyoxalase system and AGEs formation. Glucose uptake and glucose oxidation to CO2 increased in 1?h and the conversion of glucose to lipids increased at 3?h. In addition, glycine oxidation to CO2 and conversion of glycine to lipids increased at 1?h, whereas the incorporation of glycine in proteins decreased at 1 and 3?h. Methylglyoxal decreased glyoxalase I and II activities and increased AGEs content within 24?h. Lactate oxidation and lactate levels were not modified by methylglyoxal exposure. These data provide evidence that methylglyoxal may impair glucose metabolism and can affect glyoxalase activity. In periods of increased methylglyoxal exposure, such alterations could be exacerbated, leading to further increases in intracellular methylglyoxal and AGEs, and therefore triggering and/or worsening ND. 相似文献
992.
JL Jeppesen SJ Nielsen C Torp-Pedersen TW Hansen MH Olsen ND Berg A Linneberg S Madsbad M Fenger 《American journal of hypertension》2012,25(10):1095-1100
BackgroundIn a large collaborative study (n > 50,000), common variants in the natriuretic peptide (NP) genes were found to be associated with circulating NP levels and also with blood pressure (BP) levels based on office BP measurements (OBPMs). It is unknown if determining an individual's BP by 24-h ambulatory BP measurements (ABPMs) will influence the effect of NP gene variations on BP levels.MethodsWe used rs632793 at the NPPB (NP precursor B) locus to investigate the relationship between genetically determined serum N-terminal pro-brain NP (NT-proBNP) concentrations and BP levels determined by both 24-h ABPMs and OBPMs in a population consisting of 1,397 generally healthy individuals taking no BP-lowering drugs.Resultsrs632793 was significantly correlated with serum Nt-proBNP levels (r = 0.10, P = 0.0003), and participants with the A:A genotype had lower serum Nt-proBNP levels than participants with the G:G genotype (geometric mean (95% confidence interval (CI)): 34.8 (31.5-38.4) pg/ml vs. 48.1 (41.9-55.3) pg/ml, P = 0.0002), but higher 24-h ambulatory BP levels (mean difference (95% CI): 2.0 (0.1-4.1) mm Hg, P = 0.043, for systolic BP and 1.7 (0.4-3.1) mm Hg, P = 0.011, for diastolic BP). Office BP decreased across the genotypes from A:A to G:G, but the differences did not reach statistical significance (P ≥ 0.12).ConclusionsThis study suggests that 24-h ABPMs is a better method than OBPMs to detect significant differences in BP levels related to genetic variance and provides further evidence that the NP system plays an important role in BP regulation.American Journal of Hypertension 2012; doi:10.1038/ajh.2012.96. 相似文献
993.
The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients
Kasenda B Rehberg M Thürmann P Franzem M Veelken H Fritsch K Schorb E Finke J Lebiedz D Illerhaus G 《Annals of hematology》2012,91(8):1257-1264
Studies on pharmacokinetics and pharmacodynamics of high-dose methotrexate chemotherapy (HD-MTX) in elderly primary central nervous system lymphoma (PCNSL) patients are rare. MTX exposure time has recently been proposed as an outcome determining factor in PCNSL. We investigated 49 immunocompetent PCNSL patients (female N=30, male N=19, median age 73 years) who were treated according to HD-MTX-based protocols. A two-compartment pharmacokinetic model was used to describe the MTX clearance. Response to treatment was assessed by MRI. We used multivariable models to investigate the association between MTX exposure and tumor response as well as survival. Dose normalized MTX peak serum levels [C (max), μmol/L g] and dose normalized area under the curve [AUC(dn), μmol h/L g] were higher in females than in males, respectively [59.4 (f) vs. 48.1 (m), P<0.001; 373.2 (f) vs. 271.9 (m), P=0.008]. Increasing AUC was inversely correlated with tumor response. AUC values above 2,126 h?μmol/L were independently associated with shorter overall and progression-free survival [hazard ratio (HR), 4.56, 95 % CI 1.74-11.94; HR 2.87, 95 % CI 1.18-7.00]. Exceedingly high MTX AUC levels can have a negative impact on progression-free and overall survivals in elderly PCNSL patients. 相似文献
994.
995.
996.
997.
Valent P Gastl G Geissler K Greil R Hantschel O Lang A Linkesch W Lion T Petzer AL Pittermann E Pleyer L Thaler J Wolf D 《Critical reviews in oncology/hematology》2012,82(3):370-377
Nilotinib is a second generation ABL tyrosine kinase inhibitor (TKI) that exerts major anti-leukemic effects in newly diagnosed patients with chronic myeloid leukemia (CML) as well as in most patients with imatinib-resistant CML. In freshly diagnosed patients, the anti-leukemic activity of nilotinib exceeds the efficacy of imatinib, and although long-term data for nilotinib are not available yet, the drug has recently been approved for firstline treatment of chronic phase CML in various countries. Still however, several questions concerning the optimal dose, follow-up parameters, long-term safety, and patient selection remain open. Likewise, it remains uncertain whether both Sokal low-risk and high-risk patients should receive nilotinib as frontline therapy in the future. Another question is whether nilotinib can completely eradicate CML in a subset of patients. Furthermore, it remains unclear whether and what comorbidity must be regarded as relative or absolute contra-indication for this TKI. To discuss these issues, the Austrian CML Working Group organized a series of meetings in 2010. In the current article, the outcomes from these discussions are summarized and presented together with recommendations for frontline use of TKIs in various groups of patients with CML. These recommendations should assist in daily practice as well as in the preparation and conduct of clinical trials. 相似文献
998.
Mabo P Defaye P Mouton E Cebron JP Davy JM Tassin A Babuty D Mondoly P Paziaud O Anselme F Daubert JC 《Journal of cardiovascular electrophysiology》2012,23(8):853-860
Impact of Recalls on ICD Utilization . Introduction: The study was designed to evaluate the feasibility and performance of right ventricular (RV) mid‐septal versus apical implantable defibrillator (ICD) lead placement. Methods and Results: SEPTAL is a randomized, noninferiority trial, which randomly assigned patients to implantation of ICD leads in the RV mid‐septum versus apex, with a primary objective of comparing the implant success rate of implant at each site, based on strict electrical predefined criteria. We also compared the (1) pacing lead characteristics, (2) rates of appropriate and inappropriate ICD therapies, and (3) all‐cause mortality between the 2 sites at 1 year. The trial enrolled 215 patients (mean age = 59.7 ± 12.4 years, mean LVEF = 34.0 ± 14.2%, 84.2% men), of whom 148 (68.8%) presented with ischemic heart disease. The ICD indication was primary prevention in 117 patients (54.4%). The lead was successfully implanted in 96/107 patients (89.7%) assigned to the RV mid‐septum, and in 99/108 (91.7%) assigned to the apex (ns). The 1‐year rate of lead‐related adverse events was similar in both groups. A total of 8 first inappropriate ICD therapies (7.9%) were delivered in the RV mid‐septal group, versus 8 (7.8%) in the apical group (ns), while first appropriate therapies were delivered to 22 (21.4%) and 24 patients (23.8%), respectively (ns). All‐cause mortality was 7.9% in the RV mid‐septal versus 2.9% in the RV apical group (ns). Conclusion: This study confirmed the technical feasibility and noninferior performance of ICD leads implanted in the RV mid‐septum versus the apex. (J Cardiovasc Electrophysiol, Vol. 23, pp. 853‐860, August 2012) 相似文献
999.
1000.